If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
174
results.
Updated on
14/09/2026 [08:14:00]
Results 100 to 125 of 174
Absstract of: TW202521108A
Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.
Absstract of: WO2025137077A1
Compositions and methods are disclosed herein for the treatment of Alzheimer's disease with allogeneic mesenchymal stem cells. The methods of treatment involve the administration of a composition of allogeneic mesenchymal stem cells to a subject in need thereof, wherein the efficacy of the treatment methods can be determined through the measurement of specific biomarkers and improved cognitive function and/or quality of life.
Absstract of: NZ806378A
The present invention relates to the medical field, in particular to the treatment of neurological disorders. More specifically the present invention relates to the use of a nanoparticle or nanoparticles’ aggregate in the manufacture of a medicament for preventing or treating a neurological disease such as Parkinson’s disease or Alzheimer’s disease, such that the medicament is to be provided for intra-cranial or intra-thecal administration. The nanoparticle’s or nanoparticles’ aggregate’s material is a conductor material selected from iridium, palladium or platinum, or an insulator material that is rhenium(IV) oxide or hafnium(IV) oxide. The median largest size of the core of the nanoparticle or nanoparticles’ aggregate of the population is between at least 30 nm and 150 nm. The core of the nanoparticle or nanoparticles’ aggregate is coated with a biocompatible coating providing a neutral or a negative surface charge.
Absstract of: WO2026158331A1
Provided are a traditional Chinese medicine for preventing and/or treating Parkinson's disease and a method for preparing same. The traditional Chinese medicine comprises the following raw materials in parts by weight: 10-15 parts of Gastrodiae Rhizoma, 5-10 parts of Juglandis Semen, 30-40 parts of honey, 30 parts of Rosa roxburghii, and 5-8 parts of lemon. The traditional Chinese medicine has significant effects on the prevention and/or treatment of Parkinson's disease, and features simple composition, mild adverse effects, and good drug stability.
Absstract of: WO2026161463A1
Disclosed is a method of diagnosing a subject with ALS, the method including measuring the amount of OxPL on apolipoprotein E, E2, E3 and/or E4.
Absstract of: WO2026158687A1
The present invention relates to the technical field of antibody drugs, and in particular, to an anti-N3pE amyloid-β antibody and the use thereof, and a pharmaceutical composition containing the anti-N3pE amyloid-β antibody. The anti-N3pE amyloid-β antibody exhibits a significantly excellent affinity, stability and specificity. In addition, further provided is the use of the anti-N3pE amyloid-β antibody for treating diseases caused by amyloid-β (e.g., Alzheimer's disease, Down syndrome, cerebral amyloid angiopathy, etc.).
Absstract of: WO2026159574A1
A synaptic connector that promotes the formation of dopamine synapse, the synaptic connector being a molecule capable of connecting a deleted in colorectal cancer (DCC) protein present on the surface of the front part of dopamine synapse and a delta-type glutamate receptor (GluD) protein present on the surface of the rear part of dopamine synapse.
Absstract of: US20260217699A1
0000 The invention provides berberine tauroursodeoxycholate (BTUDC), pharmaceutical compositions and methods of use thereof for the treatment, reduction and/or prevention of Parkinson's disease, or an associated disease and disorder, as monotherapy or in combination with other agents or as an adjuvant. The invention further provides pharmaceutical compositions and methods of use of berberine (BBR) and tauroursodeoxycholic acid (TUDCA) for the treatment, reduction and/or prevention of Parkinson's disease, or an associated disease and disorder, as monotherapy or in combination with other agents or as an adjuvant.
Absstract of: US20260216372A1
The disclosure relates to compositions and methods for altering, e.g., enhancing, the expression of GCase proteins, whether in vitro and/or in vivo. Such compositions include delivery of an adeno-associated viral (AAV) particle. The compositions and methods of the present disclosure are useful in the treatment of subjects diagnosed with, or suspected of having Parkinson's Disease (PD), Gaucher Disease (GD), Dementia with Lewy Bodies (DLB), or related condition resulting from a deficiency in the quantity and/or function of GBA1 gene product or associated with decreased expression or protein levels of GCase protein.
Absstract of: US20260219283A1
0000 Synucleinopathies are a group of neurodegenerative diseases including Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). These diseases are characterized by the aggregation and deposition of α-synuclein (α-syn) in Lewy bodies (LBs) in PD and DLB or as glial cytoplasmic inclusions in MSA. In healthy brains, only ~4% of α-syn is phosphorylated at Ser129 (pS129-α-syn), whereas >90% pS129-α-syn may be found in LBs. Embodiments of the invention include a duplex assay for both total α-synuclein and pS129-α-synuclein, which allows measuring both analytes in the same sample, leading to substantial saving in sample volume. The assays can be widely used in methods for detecting pS129-α-syn in biomedical studies including when only a limited volume of sample is available and high sensitivity is required, offering new opportunities for diagnostic biomarkers, monitoring disease progression, and quantifying outcome measures in clinical trials.
Absstract of: US20260217678A1
Indazole- and azaindazole-substituted octahydrocyclopentacpyrrole and hexahydrocyclopentacpyrrole compounds are inhibitors of LRRK2. The compounds and their pharmaceutical compositions may be used in the treatment of CNS disorders such as familial/genetic and/or sporadic Parkinson's disease, a tauopathy, or Alzheimer's disease. Indazole- and azaindazole-substituted octahydrocyclopentacpyrrole and hexahydrocyclopentacpyrrole compounds of formula (I) are inhibitors of LRRK2. The compounds and their pharmaceutical compositions may be used in the treatment of CNS disorders such as familial/genetic and/or sporadic Parkinson's disease, a tauopathy, or Alzheimer's disease.
Absstract of: US20260216139A1
Methods for regulating aberrant glia-directed engulfment and active pruning of Neuronal Receptive Endings (NRE) are provided. Such methods comprise contacting a neuronal and/or glia cell with an effective amount of a composition which is effective in modulating at least one gene and/or protein associated with glia-directed engulfment and active pruning of Neuronal Receptive Endings. Such methods are useful in treating neurological disorders such as Parkinson's disease.
Absstract of: US20260216237A1
0000 Provided herein are methods and compositions for the treatment of ALS using chlorite or a pharmaceutical composition comprising sodium chlorite, for a target ALS patient population. Also provided herein are methods for identifying a target ALS patient population likely to be responsive to treatment with chlorite or a pharmaceutical composition comprising sodium chlorite, the methods including identifying ALS patients with elevated plasma C-reactive protein (CRP) levels and/or patients age 40-65, sporadic ALS pathology, or combinations thereof.
Absstract of: US20260216351A1
Disclosed are compositions and methods of use for treating neuronal diseases such as Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, multiple sclerosis, and amyotrophic lateral sclerosis (ALS). In certain embodiments, a flavonoid, such as apigenin, is administered alone or in a pharmaceutical preparation via the nasal olfactory route. In some embodiments, the composition further comprises a porosome complex for reconstitution into neural cells. In additional embodiments, a synthetic blood-brain barrier traversing peptide is included, wherein the peptide is engineered to mimic a domain of ATP1A3 and/or Tubulin, thereby enhancing therapeutic efficacy in restoring secretory and metabolic function in neural tissue.
Absstract of: WO2026161742A1
Methods and materials for identifying mammals (e.g., humans) as having, or being likely to have or to develop, Alzheimer's disease are provided herein. In some cases, methods and materials for stratifying mammals with Alzheimer's disease are provided herein.
Absstract of: WO2026158729A2
Provided in the present application are a pathogenic factor of neurodegenerative diseases and the use thereof. The pathogenic factor of neurodegenerative diseases is a PSAP-GPR37-IL-6 signaling axis. The present application specifies for the first time the action mechanism of the PSAP-GPR37-IL-6 signaling axis as a pathogenic factor of neurodegenerative diseases (especially Parkinson's disease), and reveals that oligodendrocytes regulate the molecular pathway of neuroinflammation and neurodegenerative changes via the signaling axis, thus filling the research gap in the prior art regarding the participation of oligodendrocytes in the pathogenesis of PD.
Absstract of: EP4782452A1
A compound represented by formula (I) and a use thereof in the preparation of a drug. The invention relates to a novel compound having an IRAK4 degradation effect, which can effectively degrade IRAK4 or otherwise inhibit IRAK4 activity. The invention has very good prospects for application in IRAK4-mediated diseases, including immune diseases, tumors, Alzheimer's disease, and fibrotic diseases, and provides a new choice for clinical screening and/or preparation of drugs related to IRAK4 activity.
Absstract of: TW202530251A
The present invention relates to therapeutical uses of non-classical human major histocompatibility complex (MHC) molecules (also named MHC class Ib molecules) in combination with peptide antigens for the treatment of neuromyelitis optica (NMO). The invention more specifically relates to recombinant polypeptides comprising peptide antigens and one or more domains of a non-classical MHC class Ib molecule. The invention also relates to methods of producing such recombinant polypeptides, pharmaceutical compositions comprising the same, as well as their uses for treating neuromyelitis optica (NMO).
Absstract of: EP4782449A1
0001 The present invention provides a use of an SARM1 enzyme activity inhibitor in treating neurodegenerative diseases or neurological diseases or conditions, and specifically provides a compound of formula (I) acting as an SARM1 enzyme activity inhibitor, and a pharmaceutical composition thereof.
Absstract of: WO2025061918A1
The present invention relates to therapeutical uses of non-classical human major histocompatibility complex (MHC) molecules (also named MHC class Ib molecules) in combination with peptide antigens for the treatment of Parkinson's disease. The invention more specifically relates to recombinant polypeptides comprising peptide antigens and one or more domains of a non-classical MHC class Ib molecule. The invention also relates to methods of producing such recombinant polypeptides, pharmaceutical compositions comprising the same, as well as their uses for treating Parkinson's disease.
Absstract of: EP4782003A1
The present application relates to a novel therapeutic agent for treating Parkinson's disease and a method for treating Parkinson's disease using the same.
Absstract of: WO2026152239A1
The present disclosure provides oral film compositions for transmucosal delivery of xanomeline and trospium chloride for treating schizophrenia and Alzheimer's disease. The compositions comprise xanomeline or a pharmaceutically acceptable salt thereof, trospium or a pharmaceutically acceptable salt thereof, at least one film-forming polymer, and d-alpha- tocopheryl polyethylene glycol succinate (TPGS) as a permeation enhancer, wherein the composition has a pH of from about 4.5 to about 7. The formulations address challenges including poor aqueous solubility, pH-dependent stability, and permeability limitations. Buccal administration enables transmucosal absorption bypassing first-pass hepatic metabolism, thereby mitigating gastrointestinal side effects and food effects compared to conventional oral capsule formulations. The disclosure demonstrates a synergistic effect wherein co-formulation of trospium chloride with xanomeline tartrate unexpectedly enhances transmucosal permeation of trospium chloride compared to films containing trospium chloride alone. Methods of treatment and manufacturing processes are also provided.
Absstract of: WO2026156134A1
The present invention provides a compound of formula I or a pharmaceutically acceptable salt thereof T-L-B (I), useful for the modulation of TYK2 protein via degradation, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of autoimmune disorders like type 1 diabetes, ankylosing spondylitis, cutaneous lupus erythematosus, systemic lupus erythematosus, lupus nephritis, multiple sclerosis, systemic sclerosis, psoriasis, Crohn's disease, ulcerative colitis, proteasome-associated autoinflammatory syndromes (PRAAS), ISG15 deficiency, and inflammatory bowel disease; inflammatory disorders like rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, psoriasis, Crohn's disease, ulcerative colitis, STING-associated vasculopathy with onset in infancy (SAVI). and inflammatory bowel disease; proliferative disorders like hematological cancer, polycythemia vera, myelofibrosis, essential thrombocythemia, and thrombocytosis; endocrine disorders like polycystic ovary' syndrome, Crouzon's syndrome, and type 1 diabetes; neurological disorders like Alzheimer's disease. Aicardi-Goiuteieres syndrome (AGS). Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, cerebral ischemia, and neurodegenerative disease caused by traumatic injury, glutamate neurotoxicity and hypoxia: and/or disorders associated
Absstract of: WO2026156364A1
Provided herein is the identification of target proteins for determination of clinical aspects of Alzheimer's disease in a subject. Further provided are methods for diagnosing Alzheimer's disease, determining the progression or rate of memory decline of Alzheimer's disease, and predicting amyloid-tau status, brain amyloidosis status, and plasma p-tau217 status of a subject, using predictor value comparison to thresholds. Also provided are methods of selecting a subject for inclusion in a clinical trial, methods for treating the subject in need thereof, and kits providing the same.
Nº publicación: WO2026154410A1 23/07/2026
Applicant:
UNIV DEGLI STUDI DI BRESCIA [IT]
UNIV DEGLI STUDI DI MILANO [IT]
UNIVERSITA' DEGLI STUDI DI BRESCIA
UNIVERSITA' DEGLI STUDI DI MILANO
Absstract of: WO2026154410A1
Described herein are novel compounds capable of binding to the protein synapsin III and reducing the fibrillar aggregates of said protein with alpha-synuclein. The novel compounds of the invention are therefore suitable for use in the therapeutic treatment of neurodegenerative diseases such as, in particular, Parkinson's disease, Lewy body dementia, multiple system atrophy, and the Lewy body variant of Alzheimer's disease. A pharmaceutical composition comprising the compounds according to the invention in a pharmaceutically acceptable carrier, as well as in combination with optional adjuvants, stabilizers and/or preservatives, is also described.
BOPI
Electronic site
